-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy (TB) help accurately detect clinically significant prostate cancer (csPC
Recently, researchers from Germany published an article in Eur Urol Oncol evaluating the csPC detection rate of two targeted MRI/transrectal ultrasonography (TRUS) fusion biopsy methods, namely conventional TB and targeted saturation biopsy (TS).
The study was a prospective single-center design in which 170 men were biopsy
The researchers used the McNemar test to analyze PC and csPC (International Society of Urological Pathology Grade ≥2) detection rates for systemic biopsy (SB), TB, and TS, and compared
The results of the study showed that 57 men in the TS group were diagnosed with csPC and 36 men in the TB group were diagnosed with csPC
Comparison of detection rates for different methods
In summary, there was no significant difference
Original Source:
Yasemin Melisa Saner , Manuel Wiesenfarth , Vivienn Weru et al.